GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.

Number of Participants With Any Adverse Event (AE): Interim Analysis [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section.

Number of Participants With Any Adverse Event (AE): Final Analysis [ Time Frame: Post January 2006; for up to 241 weeks ] [ Designated as safety issue: No ]

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section.

blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168 [ Time Frame: Baseline (Day 1) and Weeks 48, 96, 132, and 168 ] [ Designated as safety issue: No ]

Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL.

Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.

Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point.

Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs.

Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.

Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.

Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.

Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]

The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.

Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]

The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.

Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]

The number of participants with the indicated HIV-associated conditions were assessed.

Enrollment:

753

Study Start Date:

November 2001

Study Completion Date:

October 2010

Primary Completion Date:

October 2010 (Final data collection date for primary outcome measure)

Intervention Details:

Drug: fosamprenavir (GW433908)
Drug: ritonavir

Other Names:

fosamprenavir (GW433908)

ritonavir

Detailed Description:

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

Eligibility

Ages Eligible for Study:

13 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Male or non-pregnant/non-lactating females >/=13 years of age (or >/= 18 years of age according to local requirements).

Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team.

Exclusion Criteria:

Permanent discontinuation of GW433908 in a previous study due to intolerance.

An active CDC Class C Event.

Any condition which, in the opinion of the investigator, would preclude a subject from participation.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00296504